ライフサイエンスコーパス: metastasectomy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 re in CR postoperatively, with 17% requiring metastasectomy.

2 HAI and systemic therapy was initiated after metastasectomy.

3 actors for survival in patients treated with metastasectomy.

4 astatic renal cell carcinoma with or without metastasectomy.

5 of successful chemotherapies have encouraged metastasectomy.

6 n those treated with either incomplete or no metastasectomy.

7 nts with pulmonary recurrence underwent lung metastasectomy; 3-year freedom from recurrence was 37%.

8 We review the current role of metastasectomy and factors associated with outcome.

9 Patients, disease-free after CRC metastasectomy and perioperative chemotherapy (n = 74),

10 went elective colon resection at the time of metastasectomy, and eight patients (3%) underwent this r

11 arcinoma, colorectal cancer, including liver metastasectomy, and esophageal carcinoma treated primari

12 omes in larger series of patients undergoing metastasectomy as well as the indications for the proced

13 Ten patients underwent pulmonary resection/metastasectomy at various time points, the benefit of wh

14 use of other treatment modalities, including metastasectomy, chemotherapy, and radiation, was evaluat

15 The strongest evidence in favour of metastasectomy exists for colorectal cancer, in which re

16 gest that participants treated with complete metastasectomy for stage IV metastases have enhanced ove

17 ly and patients in CR after chemotherapy and metastasectomy had a better outcome than patients with m

18 However, metastasectomy has been described for almost every organ

19 suggest that patients treated with complete metastasectomy have better survival and symptom control

20 Alternatively, treatment with metastasectomy (HR, 0.59; 95% CI, 0.46-0.74; P < .001) a

21 The survival benefit offered by pulmonary metastasectomies in patients with metastatic osteosarcom

22 the (societal) cost-effectiveness of hepatic metastasectomy in patients with metachronous CRC liver m

23 Hepatic metastasectomy is a cost-effective option for selected p

24 Less often, pancreatic metastasectomy is done by enucleation or a pancreas spar

25 Pancreatic metastasectomy is most often done through a formal pancr

26 A reference strategy in which metastasectomy is not offered and imaging is not perform

27 upport to the idea that if complete surgical metastasectomy is technically feasible, then surgery sho

28 tions compared with standard follow-up after metastasectomy is warranted.

29 When considering metastasectomy, more aggressive approaches are generally

30 atrial septal defect closure (23%), cardiac metastasectomies or biopsy (4%), and simultaneous corona

31 Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in

32 Analysis including metastasectomy patients made no difference in DFS or ove

33 Metastasectomy patients were to be analyzed separately b

34 After complete metastasectomy, patients were prospectively enrolled in

35 Most literature on metastasectomy pertains to the resection of disease invo

36 Interventions included metastasectomy, radiotherapy modalities, and no local tr

37 rary group of patients who had undergone CRC metastasectomy, received similar perioperative therapy,

38 l from primary colon cancer surgery to liver metastasectomy was 12 months.

39 ry complete remission (CR) was not obtained, metastasectomy was considered.

40 Metastasectomy was rare; only 3.9% of patients underwent

41 Metastasectomies were done to procure tumour tissue to g

42 High MTV and TGV in patients before metastasectomy were significantly associated with poorer

43 erapy in selected patients following hepatic metastasectomy where this aggressive approach might have

44 Metastasectomy with curative intent has become standard

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。